These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 22079761)

  • 1. The discovery of non-benzimidazole and brain-penetrant prolylcarboxypeptidase inhibitors.
    Graham TH; Shen HC; Liu W; Xiong Y; Verras A; Bleasby K; Bhatt UR; Chabin RM; Chen D; Chen Q; Garcia-Calvo M; Geissler WM; He H; Lassman ME; Shen Z; Tong X; Tung EC; Xie D; Xu S; Colletti SL; Tata JR; Hale JJ; Pinto S; Shen DM
    Bioorg Med Chem Lett; 2012 Jan; 22(1):658-65. PubMed ID: 22079761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of benzimidazole pyrrolidinyl amides as prolylcarboxypeptidase inhibitors.
    Shen HC; Ding FX; Zhou C; Xiong Y; Verras A; Chabin RM; Xu S; Tong X; Xie D; Lassman ME; Bhatt UR; Garcia-Calvo MM; Geissler W; Shen Z; Chen D; Sinharoy R; Hale JJ; Tata JR; Pinto S; Shen DM; Colletti SL
    Bioorg Med Chem Lett; 2011 Mar; 21(5):1299-305. PubMed ID: 21315588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of aminoheterocycles as potent and brain penetrant prolylcarboxypeptidase inhibitors.
    Wu Z; Yang C; Graham TH; Verras A; Chabin RM; Xu S; Tong X; Xie D; Lassman ME; Bhatt UR; Garcia-Calvo MM; Shen Z; Chen Q; Bleasby K; Sinharoy R; Hale JJ; Tata JR; Pinto S; Colletti SL; Shen DM
    Bioorg Med Chem Lett; 2012 Feb; 22(4):1727-30. PubMed ID: 22290078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new class of prolylcarboxypeptidase inhibitors, part 1: discovery and evaluation.
    Graham TH; Liu W; Verras A; Sebhat IK; Xiong Y; Bleasby K; Bhatt UR; Chen Q; Garcia-Calvo M; Geissler WM; Gorski JN; He H; Lassman ME; Lisnock J; Li X; Shen Z; Tong X; Tung EC; Wiltsie J; Xiao J; Xie D; Xu S; Hale JJ; Pinto S; Shen DM
    Bioorg Med Chem Lett; 2012 Apr; 22(8):2811-7. PubMed ID: 22444683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of benzodihydroisofurans as novel, potent, bioavailable and brain-penetrant prolylcarboxypeptidase inhibitors.
    Shen HC; Ding FX; Jiang J; Verras A; Chabin RM; Xu S; Tong X; Chen Q; Xie D; Lassman ME; Bhatt UR; Garcia-Calvo MM; Geissler W; Shen Z; Murphy BA; Gorski JN; Wiltsie J; SinhaRoy R; Hale JJ; Pinto S; Shen DM
    Bioorg Med Chem Lett; 2012 Feb; 22(4):1550-6. PubMed ID: 22264488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new class of prolylcarboxypeptidase inhibitors, part 2: the aminocyclopentanes.
    Graham TH; Liu W; Verras A; Reibarkh M; Bleasby K; Bhatt UR; Chen Q; Garcia-Calvo M; Geissler WM; Gorski JN; He H; Lassman ME; Lisnock J; Li X; Shen Z; Tong X; Tung EC; Wiltsie J; Xie D; Xu S; Xiao J; Hale JJ; Pinto S; Shen DM
    Bioorg Med Chem Lett; 2012 Apr; 22(8):2818-22. PubMed ID: 22444685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and synthesis of prolylcarboxypeptidase (PrCP) inhibitors to validate PrCP as a potential target for obesity.
    Zhou C; Garcia-Calvo M; Pinto S; Lombardo M; Feng Z; Bender K; Pryor KD; Bhatt UR; Chabin RM; Geissler WM; Shen Z; Tong X; Zhang Z; Wong KK; Roy RS; Chapman KT; Yang L; Xiong Y
    J Med Chem; 2010 Oct; 53(19):7251-63. PubMed ID: 20857914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and optimization of orally active cyclohexane-based prolylcarboxypeptidase (PrCP) inhibitors.
    Debenham JS; Graham TH; Verras A; Zhang Y; Clements MJ; Kuethe JT; Madsen-Duggan C; Liu W; Bhatt UR; Chen D; Chen Q; Garcia-Calvo M; Geissler WM; He H; Li X; Lisnock J; Shen Z; Tong X; Tung EC; Wiltsie J; Xu S; Hale JJ; Pinto S; Shen DM
    Bioorg Med Chem Lett; 2013 Dec; 23(23):6228-33. PubMed ID: 24157366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a new class of potent prolylcarboxypeptidase inhibitors derived from alanine.
    Wu Z; Yang C; Xiong Y; Feng Z; Lombardo M; Verras A; Chabin RM; Xu S; Tong X; Xie D; Lassman ME; Bhatt UR; Garcia-Calvo MM; Geissler W; Shen Z; Chen Q; Sinharoy R; Hale JJ; Tata JR; Pinto S; Shen DM; Colletti SL
    Bioorg Med Chem Lett; 2012 Feb; 22(4):1774-8. PubMed ID: 22248857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spiroindane based amides as potent and selective MC4R agonists for the treatment of obesity.
    He S; Ye Z; Dobbelaar PH; Sebhat IK; Guo L; Liu J; Jian T; Lai Y; Franklin CL; Bakshi RK; Dellureficio JP; Hong Q; Weinberg DH; Macneil T; Tang R; Strack AM; Tamvakopoulos C; Peng Q; Miller RR; Stearns RA; Chen HY; Chen AS; Fong TM; Wyvratt MJ; Nargund RP
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4399-405. PubMed ID: 20598882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery, SAR and X-ray structure of 1H-benzimidazole-5-carboxylic acid cyclohexyl-methyl-amides as inhibitors of inducible T-cell kinase (Itk).
    Moriarty KJ; Takahashi H; Pullen SS; Khine HH; Sallati RH; Raymond EL; Woska JR; Jeanfavre DD; Roth GP; Winters MP; Qiao L; Ryan D; DesJarlais R; Robinson D; Wilson M; Bobko M; Cook BN; Lo HY; Nemoto PA; Kashem MA; Wolak JP; White A; Magolda RL; Tomczuk B
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5545-9. PubMed ID: 18819799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation.
    Park JH; Jung Y; Kim TY; Kim SG; Jong HS; Lee JW; Kim DK; Lee JS; Kim NK; Kim TY; Bang YJ
    Clin Cancer Res; 2004 Aug; 10(15):5271-81. PubMed ID: 15297431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of a novel inhibitor (UM8190) of prolylcarboxypeptidase (PRCP) on appetite and thrombosis.
    Rabey FM; Gadepalli RS; Diano S; Cheng Q; Tabrizian T; Gailani D; Rimoldi JM; Shariat-Madar Z
    Curr Med Chem; 2012; 19(24):4194-206. PubMed ID: 22664251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel, orally available benzimidazoles as melanin concentrating hormone receptor 1 (MCHR1) antagonists.
    Sasmal PK; Sasmal S; Rao PT; Venkatesham B; Roshaiah M; Abbineni C; Khanna I; Jadhav VP; Suresh J; Talwar R; Muzeeb S; Receveur JM; Frimurer TM; Rist Ø; Elster L; Högberg T
    Bioorg Med Chem Lett; 2010 Sep; 20(18):5443-8. PubMed ID: 20724156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New fluorinated pyrrolidine and azetidine amides as dipeptidyl peptidase IV inhibitors.
    Hulin B; Cabral S; Lopaze MG; Van Volkenburg MA; Andrews KM; Parker JC
    Bioorg Med Chem Lett; 2005 Nov; 15(21):4770-3. PubMed ID: 16115768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyrazoles as non-classical bioisosteres in prolylcarboxypeptidase (PrCP) inhibitors.
    Graham TH; Shu M; Verras A; Chen Q; Garcia-Calvo M; Li X; Lisnock J; Tong X; Tung EC; Wiltsie J; Hale JJ; Pinto S; Shen DM
    Bioorg Med Chem Lett; 2014 Apr; 24(7):1657-60. PubMed ID: 24636945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress in brain penetration evaluation in drug discovery and development.
    Liu X; Chen C; Smith BJ
    J Pharmacol Exp Ther; 2008 May; 325(2):349-56. PubMed ID: 18203948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates.
    El Ela AA; Härtter S; Schmitt U; Hiemke C; Spahn-Langguth H; Langguth P
    J Pharm Pharmacol; 2004 Aug; 56(8):967-75. PubMed ID: 15285840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of difference in pulmonary absorption of digoxin, a P-glycoprotein substrate, in mdr1a-deficient and mdr1a-competent mice.
    Manford F; Riffo-Vasquez Y; Spina D; Page CP; Hutt AJ; Moore V; Johansson F; Forbes B
    J Pharm Pharmacol; 2008 Oct; 60(10):1305-10. PubMed ID: 18812023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.
    Graham TH
    Expert Opin Ther Pat; 2017 Oct; 27(10):1077-1088. PubMed ID: 28699813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.